YGYi-Xiao Geng

Yi-Xiao Geng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi-Xiao Geng has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Ai-Lian Du

    Department of Neurology, Songjiang Hospital, Songjiang Research Institute, State Key Laboratory of Eye Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Chen-Xi Lin

    College of Basic Medical Science, Shanghai Jiao Tong University School of medicine, Shanghai, China

    1 shared publication
  • Fei Li

    Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China

    1 shared publication
  • Gong-Jia Tao

    Department of Neurology, Songjiang Hospital, Songjiang Research Institute, State Key Laboratory of Eye Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Jia-Shuo Wen

    School of Medicine, Yunnan University, Kunming, China

    1 shared publication
  • Jie Li

    Institute of Pediatrics, National Children’s Medical Center, Children’s Hospital, Institute for Translational Brain Research, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    In vivo base editing of Chd3 rescues behavioural abnormalities in mice

    by Kan Yang, Wei-Ke Li, Yi-Xiao Geng, Shu-Qian Zhang, Shi-Hao Wu, Yan-Bo Cheng, Jun-Wen Wang, Zhan-Kui Xu, Wen-Xin Wang, Tan-Ying Zhang, et al.

    Neurodevelopmental disorders that arise from de novo mutations in chromatin-remodelling genes lack targeted treatments. Snijders Blok–Campeau syndrome (SNIBCPS)1, which is caused by pathogenic variants in CHD3, manifests with intellectual disability, autistic-like behaviours and motor deficits2. Whether somatic gene correction can reverse such phenotypes in vivo remains unknown. Here we show that modelling the recurrent CHD3 variant p.R1025W in a humanized mouse model (Chd3hR1025W/+) recapitulates key features of SNIBCPS, including reduced CHD3 protein levels and abnormalities in social communication, cognition and motor coordination. We engineered a TadA-embedded adenine base editor (TeABE) and delivered it brain-wide using a dual adeno-associated virus (AAV) system and achieved efficient on-target A•T-to-G•C correction across multiple cortical and hippocampal regions with minimal bystander activity. This intervention restored CHD3 levels and ameliorated behavioural abnormalities in vivo. Furthermore, intrathecal dual AAV delivery in nonhuman primates resulted in widespread neuronal transduction and efficient TeABE reconstitution, a result that supports its translational feasibility. These findings establish in vivo base editing as a viable therapeutic approach for CHD3-related neurodevelopmental disease. More broadly, they demonstrate that precise single-base correction in the postnatal brain can restore protein dosage and function, thereby offering a framework for the treatment of monogenic neurodevelopmental disorders.